[Clinical and therapeutical implications of molecular aspects of Dupuytren's disease pathogenesis].
Etiology and pathogenesis of Dupuytren's disease still remains unclear. This disease like other conditions resulting from chronic pathological fibrosis (organ fibromatoses, intraperitoneal adhesions, hypertrophic scars) remains a therapeutic problem. These facts substantiate fully research on processes leading to pathological changes in these diseases. The ongoing research is not only to broaden our knowledge but mainly to work out methods of causal treatment. Despite significant observations in vitro and in clinical trials, practical applications from these studies are still a way ahead. Consequently, symptomatic surgical treatment of Dupuytren's disease still remains the method of choice.
Kaniewska
Anna
A
Kinika Chirurgii Plastycznej Centrum Medycznego Kształcenia Podyplomowego, Warszawa.
Lembas
Lubomir
L
Jethon
Józef
J
D000818:Animals; D004387:Dupuytren Contracture / Q000235:genetics* / Q000378:metabolism / Q000601:surgery*; D004815:Epidermal Growth Factor / Q000378:metabolism; D005205:Fascia / Q000473:pathology; D000071938:Fasciotomy; D005353:Fibronectins / Q000378:metabolism; D020022:Genetic Predisposition to Disease; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006225:Hand / Q000473:pathology / Q000601:surgery*; D006801:Humans; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000378:metabolism
D005353:Fibronectins; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D004815:Epidermal Growth Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor